IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
November 12, 2024 16:26 ET
|
IN8bio, Inc
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
November 12, 2024 07:00 ET
|
IN8bio, Inc
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024 09:00 ET
|
IN8bio, Inc
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting
IN8bio Announces Pricing of $12.4 Million Private Placement
October 01, 2024 08:00 ET
|
IN8bio, Inc
IN8bio Announces Pricing of $12.4 Million Private Placement
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
September 04, 2024 16:01 ET
|
IN8bio, Inc
IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 29, 2024 06:05 ET
|
IN8bio, Inc
IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100
August 12, 2024 08:05 ET
|
IN8bio, Inc
IN8bio Announces FDA Guidance for Registrational Trial of INB-100 as 100% of AML Patients remain in Complete Remission
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
August 08, 2024 16:05 ET
|
IN8bio, Inc
IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 24, 2024 08:00 ET
|
IN8bio, Inc
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
June 13, 2024 16:01 ET
|
IN8bio, Inc
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100